TENDER, VOTING AND OPTION AGREEMENT, dated as of August 28, 2000 (this "Agreement"), among Foster's Brewing Group Limited, a corporation organized --------- under the laws of the State of South Australia, Commonwealth of Australia (ABN: 49 007 620...And Option Agreement • September 1st, 2000 • Beringer Wine Estates Holdings Inc • Beverages • Delaware
THIRD Amendment to License, Collaboration, and Option AgreementAnd Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This THIRD AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Third Amendment”) is made and entered into as of February 4, 2021 (the “Third Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
EIGHTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
SYNOPSYS, INC. STOCK OPTIONS GRANT NOTICE AND OPTION AGREEMENT ([INITIAL] [ANNUAL] [INTERIM] AWARD)And Option Agreement • December 14th, 2017 • Synopsys Inc • Services-prepackaged software • California
Pursuant to its 2017 Non-Employee Directors Equity Incentive Plan (the “Plan”), Synopsys, Inc. (the “Corporation”) has granted you (the “Eligible Director” or “you”) a Nonstatutory Stock Option (the “Option”) to purchase the number of shares of the Corporation’s Common Stock at the exercise price per share set forth below. The Option is subject to the terms and conditions as set forth in this Stock Options Grant Notice and Option Agreement (this “Agreement”), the Notice of Exercise attached hereto, and the Plan, which is incorporated by reference herein in its entirety. If there is any conflict between the terms in this Agreement and the Plan, the terms of the Plan will control.
THIRTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This THIRTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT, and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
AMENDMENT NO. 7 TO COLLABORATION AND OPTION AGREEMENTAnd Option Agreement • May 4th, 2015 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 7 to the Agreement (this “Amendment No. 7”) is entered into as of March 19, 2015 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics” or “CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
ELEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This ELEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Eleventh Amendment”) is made and entered into as of June 23, 2022 (the “Eleventh Amendment Effective..., and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
SEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This SEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
(this “Seventh Amendment”) is made and entered into as of January 5, 2022 (the “Seventh Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 6 TO COLLABORATION AND OPTION AGREEMENTAnd Option Agreement • August 7th, 2013 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 6 to the Agreement (this “Amendment No. 6”) is entered into as of June 11, 2013 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
FOURTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This FOURTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTIONAnd Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
SECOND Amendment to License, Collaboration, and Option AgreementAnd Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Second Amendment”) is made and entered into as of October 28, 2020 (the “Second Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
NINTH Amendment to License, Collaboration, and Option Agreement, and Option Agreement • August 2nd, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This NINTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Ninth Amendment”) is made and entered into as of March 23, 2022 (the “Ninth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS:And Option Agreement • March 30th, 1999 • Ha Lo Industries Inc • Wholesale-misc durable goods • Michigan
AMENDMENT NO. 8 TO COLLABORATION AND OPTION AGREEMENTAnd Option Agreement • March 7th, 2019 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 8 to the Agreement (this “Amendment No. 8”) is entered into as of November 30, 2016 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics” or “CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
AMENDMENT NO. 9 TO COLLABORATION AND OPTION AGREEMENTAnd Option Agreement • March 7th, 2019 • Cytokinetics Inc • Pharmaceutical preparations
This AMENDMENT NO. 9 TO COLLABORATION AND OPTION AGREEMENT (this “Amendment No. 9”) is entered into as of February 6, 2019 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics” or “CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
TWELFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This TWELFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Twelfth Amendment”) is made and entered into as of July 28, 2022 (the “Twelfth Amendment Effective Date”)..., and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
TENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT, and Option Agreement • February 28th, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
FOURTH Amendment to License, Collaboration, and Option AgreementAnd Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This FOURTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Fourth Amendment”) is made and entered into as of June 23, 2021 (the “Fourth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST Amendment to License, Collaboration, and Option AgreementAnd Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “First Amendment”) is made and entered into as of October 23, 2020 (the “First Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
License, Collaboration, and Option Agreement, and Option Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This License, Collaboration, and Option Agreement (this “Agreement”) is made and entered into as of December 21, 2019 (the “Execution Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”).
SYNOPSYS, INC. STOCK OPTIONS GRANT NOTICE AND OPTION AGREEMENT ([INITIAL] [ANNUAL OR INTERIM] AWARD)And Option Agreement • December 16th, 2011 • Synopsys Inc • Services-prepackaged software • California
Pursuant to its 2005 Non-Employee Directors Equity Incentive Plan (the “Plan”), Synopsys, Inc. (the “Corporation”) has granted you (the “Eligible Director” or “you”) a Nonstatutory Stock Option (the “Option”) to purchase the number of shares of the Corporation’s Common Stock at the exercise price per share set forth below. The Option is subject to the terms and conditions as set forth in this Stock Options Grant Notice and Option Agreement (this “Agreement”), the Notice of Exercise attached hereto, and the Plan, which is incorporated by reference herein in its entirety. If there is any conflict between the terms in this Agreement and the Plan, the terms of the Plan will control.
SIXTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
FIFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • November 3rd, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020, October 28, 2020, February 4, 2021, and June 23, 2021 (the “Original Agreement”); and WHEREAS, the Parties desire to make certain further amendments to the Original Agreement;
